Clinical trial results:
Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of 3TC (150 mg BID) plus Raltegravir (400 mg BID) switching to 3TC (300 mg QD) plus Raltegravir (1200 mg QD) : Roll-over study of the RALAM clinical trial

Summary

EudraCT number	2017-000986-60
Trial protocol	ES
Global end of trial date	24 August 2020

Results information

Result version number	v1 (current)
This version publication date	09 April 2025
First version publication date	09 April 2025

Trial information

Trial identification

Sponsor protocol code	RALAM-Roll-Over

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03311945
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Fundació Clinic per a la Recerca Biomédica
Sponsor organisation address	C/ Villarroel 170, Barcelona, Spain,
Public contact	Judit Pich, CTU - Clinical Trials Unit, jpich@recerca.clinic.cat
Scientific contact	Dr. Esteban Martinez, Hospital Clínic de Barcelona, estebanm@clinic.cat

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 August 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	24 August 2020
Global end of trial reached?	Yes
Global end of trial date	24 August 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Efficacy assessed with standard plasma HIV-1 RNA detection (limit of detection 50 copies/mL) at 48 weeks.

Protection of trial subjects:

This trial has a Data Monitoring Committee (DSMB). The trial will end if the DSMB reviews the data and detects 4 episodes of treatment failure, and subsequently every 4 new episodes of treatment failure. The study will be interrupted as soon as 5 episodes (10%) of confirmed virological failure are detected. Additionally, one of the principal inclusion criteria is that patients must have signed informed consent to participate in the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 May 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 33
Worldwide total number of subjects	33
EEA total number of subjects	33

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	33
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

All trial subjects were recruited at a single site in Spain: Hospital Clínic de Barcelona. The subjects were patients in the switch arm who completed the 24-week follow-up of RALAM (NCT02284035) study and remained virologically suppressed (viral load <50 copies/mL) on dual therapy with 3TC plus Raltegravir.
Recruitment start period: 08-May-2018

Pre-assignment

Screening details:

Selection and baseline will be done in the same visit. Performed at Week 0. During this visit, written informed consent was obtained from each patient, and demographic data, medical history, complete physical examination, and laboratory tests (including hematology, biochemistry, and plasma viral load) were performed to confirm eligibility.

Period 1

Period 1 title	Baseline
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	RAL+3TC

Arm description:

1200 mg raltegravir + 300 mg Lamivudine

Arm type	Experimental
Investigational medicinal product name	ISENTRESS
Investigational medicinal product code	ATC: J05AX08
Other name	Raltegravir
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Dose: 1200 mg once a day (QD) during 48 weeks. It will be administred orally two 600 mg film-coated tablets of Raltegravir. Each ISENTRESS film-coated tablet contains 600 mg of raltegravir (as potassium). The rest of antiretroviral medication will be obtained through the standard prescription and dispensing route in which antiretroviral drugs are dispensed on an outpatient basis by the pharmacy service of the center.

Investigational medicinal product name	Epivir
Investigational medicinal product code	ATC: J05AF05
Other name	Lamivudine, Lamivudina (3TC)
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Dose: 300 mg once a day (QD) during 48 weeks. It will be administred orally one 300 mg film-coated tablet of Lamivudine.

Number of subjects in period 1	RAL+3TC
Started	33
Completed	33

Period 2	
Period 2 title	24 weeks
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	RAL+3TC

Arm description:

1200 mg raltegravir + 300 mg Lamivudine

Arm type	Experimental
Investigational medicinal product name	ISENTRESS
Investigational medicinal product code	ATC: J05AX08
Other name	Raltegravir
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Dose: 1200 mg once a day (QD) during 48 weeks. It will be administred orally two 600 mg film-coated tablets of Raltegravir. Each ISENTRESS film-coated tablet contains 600 mg of raltegravir (as potassium).

Investigational medicinal product name	Epivir
Investigational medicinal product code	ATC: J05AF05
Other name	Lamivudine, Lamivudina (3TC)
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Dose: 300 mg once a day (QD) during 48 weeks. It will be administred orally one 300 mg film-coated tablet of Lamivudine. The rest of antiretroviral medication will be obtained through the standard prescription and dispensing route in which antiretroviral drugs are dispensed on an outpatient basis by the pharmacy service of the center.

Number of subjects in period 2	RAL+3TC
Started	33
Completed	31
Not completed	2
Adverse event, non-fatal	2

Period 3

Period 3 title	48 weeks
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	RAL+3TC

Arm description:

1200 mg raltegravir + 300 mg Lamivudine

Arm type	Experimental
Investigational medicinal product name	ISENTRESS
Investigational medicinal product code	ATC: J05AX08
Other name	Raltegravir
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Dose: 1200 mg once a day (QD) during 48 weeks. It will be administred orally two 600 mg film-coated tablets of Raltegravir. Each ISENTRESS film-coated tablet contains 600 mg of raltegravir (as potassium).

Investigational medicinal product name	Epivir
Investigational medicinal product code	ATC: J05AF05
Other name	Lamivudine, Lamivudina (3TC)
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Dose: 300 mg once a day (QD) during 48 weeks. It will be administred orally one 300 mg film-coated tablet of Lamivudine. The rest of antiretroviral medication will be obtained through the standard prescription and dispensing route in which antiretroviral drugs are dispensed on an outpatient basis by the pharmacy service of the center.

Number of subjects in period 3	RAL+3TC
Started	31
Completed	30
Not completed	1
Lack of efficacy	1

Baseline characteristics

Reporting groups	
Reporting group title	RAL+3TC
Reporting group description:	
1200 mg raltegravir + 300 mg Lamivudine	

Reporting group values	RAL+3TC	Total	
Number of subjects	33	33	
Age categorical Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous Units: years			
arithmetic mean	53.7		
standard deviation	± 12.1	-	
Gender categorical Units: Subjects			
Female	7	7	
Male	26	26	

End points

End points reporting groups

Reporting group title	RAL+3TC
Reporting group description:	
1200 mg raltegravir + 300 mg Lamivudine	
Reporting group title	RAL+3TC
Reporting group description:	
1200 mg raltegravir + 300 mg Lamivudine	
Reporting group title	RAL+3TC
Reporting group description:	
1200 mg raltegravir + 300 mg Lamivudine	

Primary: Therapeutic failure

End point title	Therapeutic failure[1]

End point description:

Therapeutic failure at week 48, includes virological failure, change in treatment for any reason, consent withdrawal, loss to follow-up or death.
It will be analysed also at Week 24.

End point type	Primary

End point timeframe:

48 weeks.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This is a single arm study.

End point values	RAL+3TC			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: Subjects				
Yes	3			
No	30			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All SAEs occurring from the signing of informed consent until 30 days after receiving the last dose of the study drug were reported.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	20.0

Reporting groups

Reporting group title	RAL/3TC

Reporting group description:

Raltegravir 1200 mg per day plus lamivudine 300 mg per day.

Serious adverse events	RAL/3TC		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 33 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	RAL/3TC		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 33 (9.09%)		
Blood and lymphatic system disorders			
Dizzines, asthenia, headache			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences (all)	3		
Gastrointestinal disorders			
Gastrointestinal toxicity, abdominal pain, diarrhea			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	3		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/38039097